BIOCAPTIVA LTD.

Company Snapshot

Founded: 2018
Entity Type: Private
Region: U.K.
Headquarter: Edinburgh, U.K.
Key Geographics: Europe
Corporate Address: Roslin Innovation Centre, Charnock Bradley Building, Easter Bush, Midlothian, EH25 9RG, U.K. Web.: www.biocaptiva.com

Company Overview

BioCaptiva Ltd. is developing technology that captures up to 100 times more cfDNA than standard liquid biopsy blood draw. This makes the technology suitable for the early detection of cancer, where very small amounts of cfDNA may be present.

The company’s lead product, BioCollector, is used alongside a standard apheresis machine, filtering cfDNA from a patient’s blood stream.

BIOCAPTIVA LTD. In Reports

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

BCC Research Market Report says clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a (CAGR) of 31.4%.

Company's Business Segments

  • Medical Device : This segment includes BioCaptis, a new medical device to help improve Cancer Detection through dramatically increasing the amount of cfDNA through the use of Apheresis for better diagnostics compared to traditional methods.

Applications/End User Industries

  • Diagnostics
  • Researchers
  • Healthcare
  • Oncology
  • Genetics
  • Biotechnology
  • Medical Devices
  • cfDNA
  • Polymer Technology
  • Life Sciences
AI Sentiment